mTOR protein inhibitors companion diagnostic - 20/20 Gene Systems

Drug Profile

mTOR protein inhibitors companion diagnostic - 20/20 Gene Systems

Alternative Names: Everolimus companion diagnostic - 20/20 Gene Systems; Temsirolimus companion diagnostic - 20/20 Gene Systems

Latest Information Update: 17 Sep 2012

Price : $50

At a glance

  • Originator 20/20 Gene Systems
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Breast cancer

Most Recent Events

  • 12 Sep 2012 Clinical trials in Breast cancer (diagnosis) in USA (ex vivo)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top